Trials / Completed
CompletedNCT01730534
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 17,190 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 40 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin 10 mg | Oral dose (od) |
| DRUG | Placebo tablet | Oral dose (od) |
Timeline
- Start date
- 2013-04-25
- Primary completion
- 2018-09-11
- Completion
- 2018-09-11
- First posted
- 2012-11-21
- Last updated
- 2019-12-26
- Results posted
- 2019-12-26
Locations
805 sites across 34 countries: United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, Vietnam
Source: ClinicalTrials.gov record NCT01730534. Inclusion in this directory is not an endorsement.